The ClearPath Vaccines Team

You are here: ClearPath Development Company » The ClearPath Vaccines Team

Tarrant

Donna Ambrosino, MD

More than 30 years developing vaccines and biologics for infectious diseases

  • CEO of MassBiologics where she invented and developed monoclonal antibodies for C. Difficile, Rabies, and HCV (Zinplava and Rabishield now licensed products)
  • Previously was Associate Professor at Harvard Medical School and Professor of Pediatrics at UMass Medical School
  • Author of over 90 publications and multiple patents
  • Advisory Committees/Study Sections : WHO, NIH

 

 

Finn

John Finch, Esq

More than 30 years of diverse business experience in financial and strategic and operational roles

  • COO of MassBiologics, FDA-licensed manufacturer of vaccines and provider of CMO services
  • CMO services including Development, Analytical, Manufacturing and Aseptic Filling for pre-IND, clinical, and licensed products
  • Led and business development in both high growth private organizations and government agencies
  • Has been responsible for providing general administration: finance, contracting, information technology, human resources and developed facilities from design through construction

 

 

Finn

Chuck Finn, PhD

More than 30 years of product development and regulatory experience covering a wide range of product types and therapeutic indications. Experience includes FDA – CBER, biopharma and CRO industry

  • RRD International, Co-Founder, Chairman and CEO, oversees RRD’s development partnerships, managed development teams in Symphony Capital partnership; established ClearPath vaccine development partnership with Astellas Pharma
  • Quintiles, SVP/head of therapeutic business units comprising infectious diseases/immunology/allergy/respiratory/ dermatology, and medical device business units for the US
  • Genetics Institute, Director of Regulatory Affairs, responsible for several clinical stage regulatory programs
  • Miles/Bayer, Associate Director of Regulatory Affairs, responsible for anti-infective regulatory programs
  • Praxis Biologics/Lederle, Sr. Scientist, Director Regulatory Affairs, Praxis developed first Haemophilus b conjugate vaccine for infants (acquired by Lederle for $238M)
  • Staff Fellow, FDA, CBER, Division of Bacterial Products (Vaccines)

 

 

Mark Leney

Mark Leney, PhD

Over 10 years of experience in the development, manufacturing, testing and clinical trials of both investigational and commercial vaccine and biologic products

  • PhD from the University of Cambridge (Mathematical and Evolutionary Biology & Anthropology)
  • Has been responsible for managing Validation, Clinical Data Management, Quality Control, Regulatory Affairs and Quality Assurance functions
  • Previously, was an Assistant Professor of Medicine at the University of Massachusetts Medical School, Adjunct Professor of Forensic Biology at Chaminade University of Honolulu, and Faculty at the University of Oxford

 

 

Francis J. Michon, PhD

Francis J. Michon, PhD

Over 25 years of experience developing vaccines to prevent serious infectious diseases

  • PhD in organic chemistry from the University of Grenoble (France)
  • While at the National Research Council of Canada was an inventor of the conjugation platform technology which led to a new class of safer and more potent bacterial vaccines for pediatric and adult populations
  • Held senior positions at North American Vaccine and Baxter Vaccines where he worked on the development and licensure of the meningococcal C conjugate vaccine, NeisVac-C™ which has generated global sales of over $2B
  • Dr. Michon is an author/co-author of over 80 publications and an inventor on over 40 patents

 

 

Sandler

Deborah Molrine, MD

More than 17 years’ experience in clinical translation of vaccines and biologics for infectious diseases

  • Previously Assistant Professor, Harvard Medical School and Professor of Pediatrics UMass Medical School
  • Deputy Director, Clinical Affairs at MassBiologics with leadership responsibility for clinical trial design, execution and analysis of multiple phase 1, phase 2 and phase 2/3 studies evaluating monoclonal antibodies targeting Clostridium difficile, hepatitis C and rabies
  • MD from University of Pennsylvania SOM and MPH from Johns Hopkins Bloomberg School of Public Health
  • Author/Co-author of over 30 publications

 

 

Sandler

Neil Sandler, MBA

Over 30 years of investment and finance experience including > $1B in biopharma development

  • Symphony Capital co-founder and Partner
  • Behrman Capital, Partner. Head of Healthcare
  • Robertson Stephens, Partner, Head of Healthcare
  • PaineWebber Development Corp., Managing Director; Director of product development investments including those with approved products for Amgen, Sanofi/Genzyme, and J&J/Centocor
  • Managed over 125 financings and M&A’s exceeding $13B

 

 

George

George Siber, MD

More than 35 years developing vaccines and therapeutic programs for infectious diseases

  • Director of Massachusetts Public Health Biologic Laboratories which developed precursor to Synagis (>$1B sales)
  • EVP/CSO Wyeth which developed Prevnar (now >$6B sales), Meningitec, Rotashield and FluMist
  • Previously was Associate Professor at Harvard Medical School
  • Recipient of 2016 Sabin Gold Medal Award
  • Advisory Committees: WHO, NIH, Gates Foundation